<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-26069" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Obsessive-Compulsive Disorder</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Brock</surname>
            <given-names>Hannah</given-names>
          </name>
          <aff>University Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Rizvi</surname>
            <given-names>Abid</given-names>
          </name>
          <aff>West Virginia University, William R Sharpe Jr Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hany</surname>
            <given-names>Manassa</given-names>
          </name>
          <aff>Icahn School of Medicine at Mount Sinai</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hannah Brock declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abid Rizvi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Manassa Hany declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>24</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-26069.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Obsessive-Compulsive Disorder (OCD) is a prevalent psychiatric disorder affecting 1% to 3% of the global population, characterized by intrusive thoughts, known as obsessions, and repetitive actions, or compulsions. These symptoms affect patients not only by consuming a significant portion of their time but also by causing marked distress and functional impairment. The complex etiology of OCD involves cognitive, genetic, and neural factors, making the condition's diagnosis challenging and necessitating the exclusion of other psychiatric conditions that present similarly. Further complicating matters, OCD frequently coexists with other psychiatric disorders, requiring comprehensive identification and treatment for optimal clinical outcomes. While the combination of medication and psychotherapy is generally effective, emerging evidence supports using neuromodulation techniques (eg, deep brain stimulation and transcranial magnetic stimulation) for treatment-resistant cases.</p>
        <p>This activity reviews the epidemiology, etiology, clinical presentation, and management of OCD, providing healthcare professionals with the knowledge and tools to improve patient care for this complex and prevalent condition. Emphasizing the importance of prompt recognition for timely diagnosis and intervention, the activity&#x000a0;presents evaluation strategies and offers guidelines for differentiating OCD from similar psychiatric disorders. Varying etiologies, clinical presentations, and prognostic factors pertinent to OCD are also reviewed. By participating in this transformative activity, healthcare professionals will augment their clinical expertise and enhance their collaborative capacities, significantly&#x000a0;improving patient care in OCD management.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the criteria utilized to diagnose a patient with obsessive-compulsive disorder.</p></list-item><list-item><p>Implement&#x000a0;evidence-based treatment plans for patients with obsessive-compulsive disorder.</p></list-item><list-item><p>Assess the diverse etiological factors contributing to obsessive-compulsive disorder.</p></list-item><list-item><p>Implement interprofessional team strategies for improving care coordination and communication to improve outcomes for patients with obsessive-compulsive disorder.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26069&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26069">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-26069.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Obsessive-compulsive disorder (OCD) is a disabling condition estimated to affect 1% to 3% of individuals throughout their lifetime.<xref ref-type="bibr" rid="article-26069.r1">[1]</xref><xref ref-type="bibr" rid="article-26069.r2">[2]</xref>&#x000a0;This psychiatric disorder is characterized by obsessions and compulsions, which consume a significant amount of time and lead to notable distress and impairment. Obsessions refer to intrusive and repetitive thoughts, urges, or mental images that are challenging to control. These thoughts often lack a clear purpose and are accompanied by distress.<xref ref-type="bibr" rid="article-26069.r3">[3]</xref> Compulsions involve repetitive actions or mental events that individuals with OCD feel compelled to perform to&#x000a0;alleviate the distress caused by the obsessions or to prevent a feared consequence from occurring.<xref ref-type="bibr" rid="article-26069.r3">[3]</xref>&#x000a0;Additionally, individuals with OCD may also engage in avoidance behaviors of obsession-triggering situations.<xref ref-type="bibr" rid="article-26069.r2">[2]</xref></p>
        <p>OCD is a heterogeneous condition that&#x000a0;arises from a complex interplay of genetic and environmental risk factors.<xref ref-type="bibr" rid="article-26069.r4">[4]</xref> Most adults are distressed by the&#x000a0;ego-dystonic nature of their obsessions and are aware that their compulsive behaviors are abnormally excessive. Children often have difficulty describing their obsessions. In OCD patients, common obsessions and their associated compulsive behaviors include fear of contamination leading to excessive cleaning, fear of harm linked to repetitive checking of security measures, intrusive, aggressive, or sexual thoughts paired with mental rituals, and a focus on symmetry accompanied by ordering or counting.<xref ref-type="bibr" rid="article-26069.r5">[5]</xref><xref ref-type="bibr" rid="article-26069.r6">[6]</xref>&#x000a0;Though hoarding behaviors are usually specific to hoarding disorder, they can occur in OCD to prevent perceived harm. These behavior sets are consistently observed worldwide, suggesting a degree of commonality in OCD symptom dimensions. OCD can also present with rarer symptoms, including scrupulosity, obsessive jealousy, and musical obsessions.<xref ref-type="bibr" rid="article-26069.r7">[7]</xref><xref ref-type="bibr" rid="article-26069.r8">[8]</xref><xref ref-type="bibr" rid="article-26069.r3">[3]</xref></p>
        <p>The understanding of OCD has evolved significantly over time. Historically framed in religious terms as a moral failing or demonic possession, OCD was first medically described by Esquirol. Freud subsequently characterized the condition using the term <italic toggle="yes">obsessive neurosis</italic>, positing that OCD originated with a regression in the anal phase of psychosexual development.<xref ref-type="bibr" rid="article-26069.r9">[9]</xref> In the third edition of the Diagnostic and Statistical Manual (DSM-III), OCD was grouped with phobias under a single diagnosis. Later, the DSM-IV classified the condition as an anxiety disorder. The DSM-5 has reclassified OCD into the category "Obsessive-Compulsive and Related Disorders," alongside conditions like hoarding and body dysmorphia. This reclassification acknowledges shared characteristics, such as phenomenology, comorbidity, and underlying neurobiological factors.<xref ref-type="bibr" rid="article-26069.r10">[10]</xref> WHO lists OCD as 1 of the 10 most disabling conditions caused by financial loss and decreased quality of life.<xref ref-type="bibr" rid="article-26069.r11">[11]</xref>&#x000a0;In The&#x000a0;Diagnostic and Statistical Manual of Mental Disorders fifth edition Text Revision&#x000a0;(DSM-5 TR), which was published by the American Psychiatric Association (APA) in 2022, OCD sits under the category of o<italic toggle="yes">bsessive-compulsive and related disorders&#x000a0;</italic>where&#x000a0;the following subcategories were placed:<xref ref-type="bibr" rid="article-26069.r3">[3]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>OCD</p>
          </list-item>
          <list-item>
            <p>Body dysmorphic disorder (BDD)</p>
          </list-item>
          <list-item>
            <p>Hoarding disorder</p>
          </list-item>
          <list-item>
            <p>Trichotillomania</p>
          </list-item>
          <list-item>
            <p>Excoriation (ie, skin-picking) disorder</p>
          </list-item>
          <list-item>
            <p>Substance or medication-induced obsessive-compulsive and related disorder</p>
          </list-item>
          <list-item>
            <p>Obsessive-compulsive and related disorder as a result of another medical condition</p>
          </list-item>
          <list-item>
            <p>Other specified obsessive-compulsive and related disorder</p>
          </list-item>
          <list-item>
            <p>Unspecified obsessive-compulsive and related disorder</p>
          </list-item>
        </list>
        <p>The diagnosis of OCD is based on clinical assessment determining whether the DSM-5 TR criteria are met, which specify that either obsessions or compulsions must be present, the behaviors must be time-consuming, taking &#x02265;1 hour per day, and significantly disrupting daily life.<xref ref-type="bibr" rid="article-26069.r3">[3]</xref>&#x000a0;(Refer to the <bold>History and Physical Examination</bold>&#x000a0;section for more information on the diagnostic criteria for OCD).&#x000a0;</p>
      </sec>
      <sec id="article-26069.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiology of OCD is complex, encompassing diverse factors, including cognitive, genetic, molecular, environmental, and neural elements. Evidence from twin studies points to a significant genetic predisposition with an estimated heritability quotient of approximately 48%.<xref ref-type="bibr" rid="article-26069.r12">[12]</xref><xref ref-type="bibr" rid="article-26069.r13">[13]</xref>&#x000a0;However, this estimate is reduced to 35% when maternal effects (eg, prenatal exposure to stress or infection) are considered.<xref ref-type="bibr" rid="article-26069.r14">[14]</xref>&#x000a0;However, despite significant efforts through candidate gene association studies, reproducible genetic markers for OCD remain elusive. Many of these studies have focused on neurotransmitter pathways involving serotonin, dopamine, and glutamate without definitive results.<xref ref-type="bibr" rid="article-26069.r12">[12]</xref>&#x000a0;Nevertheless, the gene SLC1A1, responsible for encoding the neuronal glutamate transporter EAAT3, has surfaced as a potentially significant candidate.<xref ref-type="bibr" rid="article-26069.r15">[15]</xref><xref ref-type="bibr" rid="article-26069.r12">[12]</xref></p>
        <p>Recent studies point&#x000a0;towards OCD being fundamentally a network-based disorder.<xref ref-type="bibr" rid="article-26069.r16">[16]</xref> The cortico-striato-thalamo-cortical (CSTC) loop has become a pivotal framework for understanding its pathophysiology.<xref ref-type="bibr" rid="article-26069.r16">[16]</xref> The CSTC loop involves a series of interconnected circuits that allow the prefrontal cortex to communicate with subcortical structures (eg, the striatum and the thalamus). This loop has 2 distinct pathways: the direct and the indirect. The direct pathway facilitates behavior initiation, whereas the indirect pathway inhibits or modulates these behaviors.<xref ref-type="bibr" rid="article-26069.r17">[17]</xref> In OCD, hyperactivity in the direct pathway relative to the indirect pathway has been observed. This creates an imbalance that may cause&#x000a0;repetitive, intrusive thoughts and compulsive actions.<xref ref-type="bibr" rid="article-26069.r13">[13]</xref><xref ref-type="bibr" rid="article-26069.r18">[18]</xref>&#x000a0;Recent neuroimaging studies indicate&#x000a0;heightened connectivity and activation within the CSTC loop in OCD.<xref ref-type="bibr" rid="article-26069.r13">[13]</xref>&#x000a0;Furthermore, OCD may occur with other neurological conditions that impact the CSTC circuitry, including Parkinson disease, Sydenham chorea, traumatic brain injury, Tourette syndrome, Huntington disease, and epilepsy.<xref ref-type="bibr" rid="article-26069.r19">[19]</xref><xref ref-type="bibr" rid="article-26069.r20">[20]</xref>&#x000a0;</p>
        <p>Early findings of the effectiveness of clomipramine, which has robust serotonin reuptake inhibition observed during treatment, emphasized the role of serotonin in the pathogenesis of OCD.<xref ref-type="bibr" rid="article-26069.r13">[13]</xref> However, this serotonin-centric model has faced scrutiny because other serotonin-modulating agents like buspirone and ondansetron have not proven effective in OCD.<xref ref-type="bibr" rid="article-26069.r21">[21]</xref><xref ref-type="bibr" rid="article-26069.r22">[22]</xref>&#x000a0;Emerging studies point&#x000a0;towards the glutaminergic system in the onset and progression of OCD.<xref ref-type="bibr" rid="article-26069.r13">[13]</xref> Pharmacological agents like riluzole and troriluzole, which affect&#x000a0;glutaminergic neurotransmission, have shown preliminary benefits.<xref ref-type="bibr" rid="article-26069.r23">[23]</xref><xref ref-type="bibr" rid="article-26069.r24">[24]</xref>&#x000a0;The efficacy of antipsychotic drugs when used for augmentation in OCD suggests dopamine's role in OCD pathology.<xref ref-type="bibr" rid="article-26069.r25">[25]</xref><xref ref-type="bibr" rid="article-26069.r13">[13]</xref>&#x000a0;Imaging studies corroborate this by demonstrating increased dopamine concentrations in the basal ganglia of patients with OCD. Moreover, dopamine agonists can induce OCD-like behaviors in both animals and humans. Interestingly, enhancing cortical dopamine has also shown promise in alleviating OCD symptoms.<xref ref-type="bibr" rid="article-26069.r26">[26]</xref> However, the findings are preliminary and lack direct evidence.</p>
        <p>The autoimmune etiology provides another intriguing dimension to OCD, particularly in Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS).<xref ref-type="bibr" rid="article-26069.r27">[27]</xref>&#x000a0;PANDAS is regarded as a subset of PANS. Unlike OCD, the onset of PANDAS and PANS is often sudden and severe, accompanied by additional symptoms, including handwriting deterioration, emotional lability, and episodic disease courses. These conditions are mediated by autoimmune responses triggered by infection, inflammatory reactions, or other toxins and have parallels with other autoimmune neuropsychiatric disorders (eg, Sydenham chorea).<xref ref-type="bibr" rid="article-26069.r27">[27]</xref> Preliminary research indicates that striatal cholinergic interneurons may be the cellular targets of these autoimmune responses.<xref ref-type="bibr" rid="article-26069.r28">[28]</xref>&#x000a0;</p>
        <p>Cognitive and learning-based models of OCD posit that maladaptive beliefs fuel obsessional anxiety, leading to compulsive behaviors aimed at mitigating such anxiety.<xref ref-type="bibr" rid="article-26069.r25">[25]</xref> Several cognitive impairments have been identified as contributing to obsessional anxiety, including:</p>
        <list list-type="bullet">
          <list-item>
            <p>Heightened responsibility</p>
          </list-item>
          <list-item>
            <p>Overemphasis on thoughts</p>
          </list-item>
          <list-item>
            <p>Controlling thoughts</p>
          </list-item>
          <list-item>
            <p>Threat overestimation</p>
          </list-item>
          <list-item>
            <p>Perfectionism</p>
          </list-item>
          <list-item>
            <p>Intolerance of uncertainty</p>
          </list-item>
        </list>
        <p>Empirical evidence supports the effectiveness of these models; exposure to obsession-linked stimuli increases anxiety while engaging in compulsive rituals lowers it.<xref ref-type="bibr" rid="article-26069.r25">[25]</xref> Additionally, the learning-based model argues that the underlying learning mechanisms are not inherently pathological. This aligns with the observation that nonclinical populations also experience obsessive-like thoughts without distress. These models have been instrumental in developing psychological therapies for OCD, substantiating their theoretical and practical utility.<xref ref-type="bibr" rid="article-26069.r29">[29]</xref><xref ref-type="bibr" rid="article-26069.r25">[25]</xref></p>
      </sec>
      <sec id="article-26069.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>OCD is a leading cause of psychiatric morbidity worldwide, affecting 1% to 3% of the population.&#x000a0;Frequently, OCD is associated with comorbid psychiatric conditions.<xref ref-type="bibr" rid="article-26069.r3">[3]</xref><xref ref-type="bibr" rid="article-26069.r13">[13]</xref><xref ref-type="bibr" rid="article-26069.r25">[25]</xref><xref ref-type="bibr" rid="article-26069.r30">[30]</xref>&#x000a0;OCD often has onset early in life and generally has a chronic cause. The most common demographic range affected is from ages 18 to 29 years.<xref ref-type="bibr" rid="article-26069.r3">[3]</xref> Interestingly, nearly a quarter of males display symptoms before age 10, whereas the disorder usually emerges during adolescence for females.<xref ref-type="bibr" rid="article-26069.r3">[3]</xref> Additionally, the peripartum and postpartum phases are marked as periods of increased risk for women, with OCD incidence during these times exceeding that in nonpregnant females.<xref ref-type="bibr" rid="article-26069.r31">[31]</xref> Women are also about 1.6 times as likely as men to be affected by the disorder.<xref ref-type="bibr" rid="article-26069.r32">[32]</xref></p>
        <p>A striking 90% of individuals with OCD meet the criteria for at least one additional psychiatric disorder, with anxiety disorders, mood disorders, impulse-control disorders, and substance use disorders being the most prevalent comorbid conditions.<xref ref-type="bibr" rid="article-26069.r3">[3]</xref> Despite the disorder's significant impact, OCD frequently remains both underdiagnosed and undertreated, with only a small fraction of patients receiving appropriate medical care.<xref ref-type="bibr" rid="article-26069.r3">[3]</xref><xref ref-type="bibr" rid="article-26069.r33">[33]</xref></p>
      </sec>
      <sec id="article-26069.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>While OCD is generally considered to stem from a mix of several etiological factors, some instances can be linked explicitly to neurological causes involving the basal ganglia.<xref ref-type="bibr" rid="article-26069.r12">[12]</xref> Detailed evidence supports this from case reports associated with conditions such as Sydenham's chorea and ischemic events. These conditions result in disruptions to basal ganglia regions like the globus pallidus and caudate, leading to obsessive-compulsive behaviors.<xref ref-type="bibr" rid="article-26069.r13">[13]</xref>&#x000a0;In research conducted by the Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) consortium, no marked structural brain differences were discerned between patients with OCD and healthy controls unless factoring in medication status.<xref ref-type="bibr" rid="article-26069.r34">[34]</xref> Postmortem studies, albeit limited, have revealed abnormalities in the orbitofrontal cortex of patients with OCD.<xref ref-type="bibr" rid="article-26069.r35">[35]</xref> Specifically, one such study found evidence for lower excitatory synaptic gene expression in the orbitofrontal cortex of subjects (N=8) when compared with unaffected controls.<xref ref-type="bibr" rid="article-26069.r35">[35]</xref>&#x000a0;These studies, however, have limitations, including small sample sizes.</p>
      </sec>
      <sec id="article-26069.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The diagnosis of OCD is based on clinical assessment determining whether the DSM-5 TR criteria are met, which specify that either obsessions or compulsions must be present, the behaviors must be time-consuming, taking &#x02265;1 hour per day, and significantly disrupting daily life.<xref ref-type="bibr" rid="article-26069.r3">[3]</xref></p>
        <p>
<bold>Obsessive-Compulsive Disorder Diagnostic Criteria</bold>
</p>
        <p>In DSM-5 TR, the diagnosis of&#x000a0;OCD was based on the following criteria.</p>
        <list list-type="bullet">
          <list-item>
            <p>The presence of obsessions, compulsions, or both which meet the following definitions:<xref ref-type="bibr" rid="article-26069.r3">[3]</xref>
<list list-type="bullet"><list-item><p><bold>Obsessions</bold>
<list list-type="bullet"><list-item><p>Recurrent and persistent thoughts, urges, or images that are experienced at some time during the disturbance are intrusive and unwanted and, in most individuals, cause&#x000a0;marked anxiety or distress.</p></list-item><list-item><p>The individual attempts to suppress such thoughts, urges, or images with some other thought or action (ie, by replacing them with a compulsion).</p></list-item></list>
</p></list-item><list-item><p><bold>Compulsions</bold>
<list list-type="bullet"><list-item><p>Repetitive behaviors or mental acts that the person feels driven to perform in response to an obsession&#x000a0;or according to rules that must be applied rigidly.</p></list-item><list-item><p>The behaviors or mental acts aim at reducing anxiety or distress or preventing some dreaded situation; however, these behaviors or mental actions do not connect realistically with what they are designed to&#x000a0;or are excessive.</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The obsessions are time-consuming or cause clinically significant distress or impairment in social, occupational, or other critical functional areas.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Obsessive-compulsive symptoms do not arise from the physiological effects of a substance (eg, a drug of abuse, a medication) or another medical condition.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>The symptoms of another mental disorder do not better explain the disturbance. Differential diagnoses should be considered before an OCD diagnosis is made.&#x000a0;(Refer to the <bold>Differential Diagnoses</bold>&#x000a0;section for more information on conditions with clinical features similar to&#x000a0;OCD.) These symptoms should not be attributable to other psychiatric or medical disorders. The belief that obsessions lead to compulsions is common; however, the relationship between the conditions is not always straightforward. Theoretically, obsessions and compulsions can occur independently of each other. Patients with OCD typically seek outpatient care and often possess insight into their condition, although exceptions exist in children or severe cases. These individuals usually experience distress due to the ego-dystonic nature of their symptoms.</p>
          </list-item>
        </list>
        <p>
<bold>Clinical Assessment</bold>
</p>
        <p>A thorough medical history and mental status examination are vital in diagnosing the condition, differentiating OCD from other disorders, gauging prognosis, and devising a treatment plan. During the assessment, determining whether the patient is grappling with obsessions, compulsions, or both is critical. Symptoms should also be categorized into the following specific dimensions.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Contamination</bold>: cleanliness obsessions and cleaning compulsions</p>
          </list-item>
          <list-item>
            <p><bold>Harmful thoughts</bold>: fears of causing harm and compulsive checking</p>
          </list-item>
          <list-item>
            <p><bold>Forbidden thoughts</bold>: aggressive, sexual, or religious obsessions with corresponding mental rituals;&#x000a0;often suggest a worse prognosis.<xref ref-type="bibr" rid="article-26069.r3">[3]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p><bold>Symmetry</bold>: compulsions (eg, repeating, ordering, and counting)&#x000a0;<xref ref-type="bibr" rid="article-26069.r3">[3]</xref><xref ref-type="bibr" rid="article-26069.r25">[25]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>Safety assessments are also conducted to look for immediate risks to the patient or others. Screening for comorbid conditions, including depression, bipolar disorder, and other anxiety disorders, should be performed, and the patient's past psychiatric and general medical history should be reviewed. All medications, supplements, and known allergies or sensitivities should be obtained also. Furthermore, clinicians should gather pertinent information on the patient's psychosocial background, including familial relationships, stressors, and educational history. A family history focusing on OCD and other psychiatric conditions is also obtained to provide a holistic view of the patient's health.</p>
        <p>Additionally, OCP may have specific nuances in its presentation, such as with postpartum OCD, with which clinicians should be familiar. For instance, some new mothers may experience distressing, obsessive thoughts about harming their baby and may be reluctant to disclose these for fear of judgment or consequences. In such sensitive cases, building rapport and ensuring a confidential and nonjudgmental setting for disclosure becomes paramount. However, the clinician must vigilantly assess the safety of the patient and the child. An&#x000a0;individualized treatment plan for each patient should be created using a comprehensive approach.</p>
        <p>
<bold>Mental Status Examination</bold>
</p>
        <p>The mental status examination (MSE)&#x000a0;for patients with OCD may differ depending upon the severity of symptoms, specific manifestations of the disorder, and any coexisting conditions. The following are some MSE findings that are common during the clinical assessment.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Appearance and behavior:</bold> Patients generally present as well-groomed but exhibit visible anxiety. Manifestations of OCD, such as frequent hand-washing, checking behaviors, or rearrangement of objects, are often observed during the interview and serve as a diagnostic indicator.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Psychomotor activity:</bold>&#x000a0;Individuals are observed engaging in repetitive actions (eg, tapping, checking, or constantly washing their hands). These behaviors are compulsively performed, even when causing visible distress to the patient.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Speech:</bold> While articulation is generally coherent and goal-oriented, intrusive thoughts may periodically disrupt the flow of speech. Depending on the individual, these thoughts may or may not be vocalized during the examination.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Mood and affect:</bold> Patients usually report feelings of anxiety or distress, and their emotional expression (ie, affect) appears consistent with these reported experiences, often displaying heightened signs of stress.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Thought content:</bold> Obsessive thoughts differ among patients but commonly revolve around themes like contamination, harm to oneself or others, a quest for symmetry, or distressing sexual or religious beliefs. Compulsions to counteract these obsessions are frequently reported.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Thought process:</bold> Generally linear and coherent, intrusive, obsessive thoughts&#x000a0;intermittently interrupt the thought process. Patients usually acknowledge these thoughts as irrational yet find themselves compelled to respond with corresponding compulsions.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Perceptual abnormalities:</bold> Unlike some other psychiatric disorders, hallucinations or illusions are seldom observed in OCD patients.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Cognition:</bold> Patients typically remain alert and oriented to time, place, and person. Overall cognitive function is usually preserved, although sometimes compromised by the pervasive nature of the obsessive thoughts.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Insight and judgment:</bold> A significant feature in most OCD cases is the preservation of insight. Patients often recognize the irrational nature of their obsessions and compulsions but report feeling powerless to control them. Judgment may specifically falter when resisting the urge to perform compulsive behaviors.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26069.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Screening for the correct symptoms of&#x000a0;OCD is essential. A common tool is the short OCD screener. At 6 questions long and a sensitivity of 97%, this screening modality is a simple and effective way to identify patients with symptoms of OCD.<xref ref-type="bibr" rid="article-26069.r36">[36]</xref>&#x000a0;However, the most widely accepted tool to screen for OCD is the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS).<xref ref-type="bibr" rid="article-26069.r37">[37]</xref>&#x000a0;The Y-BOCS rates on a scale from 0&#x000a0;to 40, with 40 indicating the most severe symptomatology.<xref ref-type="bibr" rid="article-26069.r38">[38]</xref>&#x000a0;This scale requires the patient to rank the following based on severity:<xref ref-type="bibr" rid="article-26069.r38">[38]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Time occupied by obsessive thoughts and compulsions</p>
          </list-item>
          <list-item>
            <p>Interference of obsessive thoughts</p>
          </list-item>
          <list-item>
            <p>Distress of obsessive thoughts</p>
          </list-item>
          <list-item>
            <p>Resistance&#x000a0;against obsessions</p>
          </list-item>
          <list-item>
            <p>Degree of&#x000a0;control&#x000a0;over obsessive thoughts</p>
          </list-item>
          <list-item>
            <p>Time occupied by compulsive behavior</p>
          </list-item>
          <list-item>
            <p>Interference of compulsive behavior</p>
          </list-item>
          <list-item>
            <p>Distress associated with compulsive behavior</p>
          </list-item>
          <list-item>
            <p>Resistance against compulsive behavior</p>
          </list-item>
          <list-item>
            <p>Degree of control over compulsive behaviors</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26069.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Psychotherapy</bold>
</p>
        <p>Cognitive-behavioral therapy (CBT) is an evidence-based psychotherapeutic intervention for OCD.<xref ref-type="bibr" rid="article-26069.r39">[39]</xref><xref ref-type="bibr" rid="article-26069.r40">[40]</xref>&#x000a0;Within the framework of CBT, exposure and response prevention (ERP) emerges as the most empirically substantiated behavioral technique. ERP entails subjecting patients to stimuli that provoke anxiety while guiding them to abstain from subsequent compulsive behaviors.<xref ref-type="bibr" rid="article-26069.r41">[41]</xref> Various delivery modalities, including individual and group settings, as well as in-person and internet-based formats, have proven effective in treating OCD.<xref ref-type="bibr" rid="article-26069.r41">[41]</xref></p>
        <p>A key determinant of therapeutic efficacy is the patient&#x02019;s adherence to at-home assignments, most notably those involving home-based ERP exercises. CBT serves as a first-line treatment for OCD, especially when this technique aligns with the patient&#x02019;s treatment preferences, access to qualified clinicians is available, and no compelling comorbid conditions necessitate pharmacotherapy. Although meta-analyses suggest that CBT often outperforms pharmacological interventions, such conclusions should be drawn cautiously, taking into account variables such as patient selection criteria and baseline severity of OCD symptoms.<xref ref-type="bibr" rid="article-26069.r3">[3]</xref>&#x000a0;Emerging research indicates that intensive CBT protocols, often condensed into a brief period and occasionally administered in an inpatient context, hold promise for both initial and advanced treatment of severe OCD cases.<xref ref-type="bibr" rid="article-26069.r42">[42]</xref></p>
        <p>
<bold>Pharmacotherapy</bold>
</p>
        <p>Selective serotonin reuptake inhibitors (SSRIs) are recommended as the first-line medications due to their proven efficacy, safety, and tolerability.<xref ref-type="bibr" rid="article-26069.r43">[43]</xref> Higher dosages than those used for other anxiety disorders or major depressive disorder are typically prescribed, improving effectiveness&#x000a0;but increasing the risk of adverse effects such as gastrointestinal and sexual complications.<xref ref-type="bibr" rid="article-26069.r44">[44]</xref> Therefore, careful assessment of side effects is critical for individual dosage optimization. Uniform effect sizes of commonly used SSRIs have been observed in systematic reviews, yet each SSRI has its adverse effect&#x000a0;profile.<xref ref-type="bibr" rid="article-26069.r45">[45]</xref>.</p>
        <p>Selection criteria of SSRIs for OCD include prior treatment response, adverse event potential, drug interactions, coexisting medical conditions, and cost and availability of the drug.<xref ref-type="bibr" rid="article-26069.r3">[3]</xref>&#x000a0;Treatment guidelines recommend an 8- to 12-week SSRI trial to determine efficacy. However, recent meta-analyses show significant symptom improvement within the first 2 weeks of SSRI treatment.<xref ref-type="bibr" rid="article-26069.r46">[46]</xref><xref ref-type="bibr" rid="article-26069.r47">[47]</xref>. An open-label fluoxetine study indicated that early symptom reduction within 4 weeks predicted 12-week treatment success.<xref ref-type="bibr" rid="article-26069.r48">[48]</xref> Maintenance treatment is generally advised for at least 12 to 24 months postremission, but longer durations may be needed due to relapse risk upon medication discontinuation.<xref ref-type="bibr" rid="article-26069.r49">[49]</xref></p>
        <p>Clomipramine, a tricyclic antidepressant (TCA), was the first drug to show efficacy in treating OCD. Meta-analyses suggest its higher efficacy compared to SSRIs, but this finding requires caution as early clomipramine studies included fewer treatment-resistant patients. Direct comparisons indicate equivalent efficacy between clomipramine and SSRIs. SSRIs are preferred for long-term treatment due to&#x000a0;their superior safety profiles and tolerability than other antidepressants.<xref ref-type="bibr" rid="article-26069.r3">[3]</xref>&#x000a0;</p>
        <p>Approximately half of patients with OCD fail to respond to first-line treatments.<xref ref-type="bibr" rid="article-26069.r50">[50]</xref> Factors predicting poor response include higher symptom severity, marked functional impairments, specific obsession and compulsion subtypes (eg, sexual, religious, and hoarding), limited insight, high comorbidity rates, and lack of adherence to treatment protocols.<xref ref-type="bibr" rid="article-26069.r3">[3]</xref>&#x000a0;Combinatorial strategies involving CBT and SSRIs can be effective for those demonstrating poor response.<xref ref-type="bibr" rid="article-26069.r3">[3]</xref> However, CBT is frequently constrained by availability or patient intolerance to exposure techniques.</p>
        <p>Alternative approaches include switching SSRIs, using supratherapeutic doses, or switching to serotonin-noradrenaline reuptake inhibitors.<xref ref-type="bibr" rid="article-26069.r3">[3]</xref>&#x000a0;SSRIs may also be augmented with antipsychotics, tricyclic antidepressants (eg, clomipramine), or glutamatergic agents.<xref ref-type="bibr" rid="article-26069.r51">[51]</xref><xref ref-type="bibr" rid="article-26069.r52">[52]</xref><xref ref-type="bibr" rid="article-26069.r3">[3]</xref>&#x000a0;The combination of fluoxetine and clomipramine outperforms fluoxetine with an antipsychotic. However, the&#x000a0;fluoxetine and clomipramine combination carries the risk of elevated blood levels of both drugs, leading to potentially severe adverse events (eg, seizures, cardiac arrhythmias, and serotonergic syndrome).<xref ref-type="bibr" rid="article-26069.r53">[53]</xref> Augmentation with antipsychotics, especially risperidone and aripiprazole, shows some evidence of efficacy; however, only one-third of SSRI-resistant patients experience clinically meaningful improvements, warranting meticulous risk-benefit evaluations.<xref ref-type="bibr" rid="article-26069.r51">[51]</xref>&#x000a0;Glutamatergic system modulators (eg, memantine,&#x000a0;N-acetylcysteine, lamotrigine, topiramate, riluzole, troriluzole, and ketamine) have been explored as augmentation therapies and have shown some promise.<xref ref-type="bibr" rid="article-26069.r3">[3]</xref>&#x000a0;Among these, N-acetylcysteine has the most substantial amount of evidence.<xref ref-type="bibr" rid="article-26069.r54">[54]</xref></p>
        <p>
<bold>Neuromodulation</bold>
</p>
        <p>In addition to the established treatment options such as Exposure and Response Prevention (ERP), Serotonin Reuptake Inhibitors (SRIs), and antipsychotic augmentation of SRIs, there exists a limited array of other evidence-based alternatives. Nonetheless, several treatment modalities have shown promise for cases refractory to standard interventions.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Transcranial magnetic stimulation</bold>: Studies employing repetitive transcranial magnetic stimulation (rTMS) targeted at various brain regions (eg, the dorsolateral prefrontal cortex [dlPFC], dorsomedial prefrontal cortex [dmPFC], and orbitofrontal cortex [OFC]) have yielded mixed outcomes. However, these studies generally support the idea of cortico-striatal hyperactivity as an underlying factor in OCD.<xref ref-type="bibr" rid="article-26069.r55">[55]</xref> Deep transcranial magnetic stimulation (dTMS), which utilizes an H-shaped coil, can reach depths of 3 to 5 cm, targeting midline structures such as the medial prefrontal cortex (mPFC) and anterior cingulate cortex (ACC). These areas are believed to be hyperactive in OCD.<xref ref-type="bibr" rid="article-26069.r56">[56]</xref> Significantly, dTMS has gained US Food and Drug Administration (FDA) approval for the treatment of OCD.<xref ref-type="bibr" rid="article-26069.r57">[57]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Stereotactic ablation</bold>: The introduction of the stereotaxic frame during the last century significantly improved the accuracy of lesion-based treatments for persistent psychiatric disorders. Dorsal anterior cingulotomy and anterior capsulotomy are the most commonly employed ablation methods. The former disrupts the cingulum bundle to sever communication among essential limbic regions, while the latter isolates the anterior limb of the internal capsule to disconnect the OFC and dACC.<xref ref-type="bibr" rid="article-26069.r58">[58]</xref>. Both interventions are designed to regulate hyperactive CSTC circuits, which are believed to underlie OCD.<xref ref-type="bibr" rid="article-26069.r59">[59]</xref> Cingulotomy has shown 41%, whereas capsulotomy had a 54% effectiveness rate.<xref ref-type="bibr" rid="article-26069.r58">[58]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Deep brain stimulation</bold>:&#x000a0;Deep brain stimulation (DBS) is a reversible, adjustable treatment for intractable OCD with response rates between 40% and 70%, involving the neurosurgical implantation of an electrode that can activate neighboring neural circuitry.<xref ref-type="bibr" rid="article-26069.r60">[60]</xref><xref ref-type="bibr" rid="article-26069.r13">[13]</xref>&#x000a0;DBS targets the anterior limb of the internal capsule and the ventral striatum (VS). Regulatory endorsements exist, but adoption is limited by cost and required expertise.<xref ref-type="bibr" rid="article-26069.r13">[13]</xref> Electrode placement remains under debate, focusing on deep gray matter structures (eg, VS or nucleus accumbens [NAc], anterior limb of the internal capsule, and subthalamic nucleus [STN]) or white matter pathways connecting the prefrontal cortex to the thalamus.<xref ref-type="bibr" rid="article-26069.r61">[61]</xref> Emerging research challenges the notion of high-frequency DBS as &#x0201c;functional ablation,&#x0201d; pointing to complex therapeutic mechanisms.<xref ref-type="bibr" rid="article-26069.r13">[13]</xref>&#x000a0;DBS modulates activity in brain regions linked to OCD, and the degree of modulation correlates with symptom improvement. Different DBS targets may yield specific benefits; ventral capsule (VC) and VS targeting improve comorbid depression, while STN targeting improves cognitive flexibility.<xref ref-type="bibr" rid="article-26069.r62">[62]</xref>&#x000a0;Future DBS targeting may be individualized based on clinical or neurobiological measures.<xref ref-type="bibr" rid="article-26069.r13">[13]</xref>&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26069.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>OCD has symptoms similar to several other psychiatric conditions. Differentiating OCD from these conditions is essential for accurate diagnosis and effective treatment planning, as part of the criteria for OCD diagnosis involves ensuring that the symptoms of another mental disorder do not better explain the disturbance. However, OCD may also occur along with other psychiatric disorders, which can complicate clinical diagnosis. The following are some commonly considered differential diagnoses and the features that can separate from OCD:<xref ref-type="bibr" rid="article-26069.r3">[3]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Generalized Anxiety Disorders</bold>: OCD involves irrational or odd obsessions, distinct from real-life worries found in generalized anxiety disorder. Compulsions are typically present in OCD but not in anxiety disorders.</p>
          </list-item>
          <list-item>
            <p><bold>Specific Phobia</bold>: Unlike OCD, fears in specific phobia are circumscribed to particular objects or situations and don't involve rituals or compulsions.</p>
          </list-item>
          <list-item>
            <p><bold>Social Anxiety Disorder</bold>: Fears with this condition are related to social interactions, and avoidant behaviors are aimed at reducing social fears rather than neutralizing obsessions.</p>
          </list-item>
          <list-item>
            <p><bold>Major Depressive Disorder</bold>: Ruminative thoughts in major depressive disorder (MDD) are mood-congruent and not linked to compulsive behaviors, unlike the intrusive obsessions in OCD.</p>
          </list-item>
          <list-item>
            <p><bold>Body Dysmorphic Disorder:</bold>&#x000a0;This condition involves obsessions and compulsions related only to physical appearance.</p>
          </list-item>
          <list-item>
            <p><bold>Trichotillomania:</bold> Compulsive hair-pulling without the presence of obsessions differentiates trichotillomania from OCD.</p>
          </list-item>
          <list-item>
            <p><bold>Hoarding Disorder:</bold>&#x000a0;Difficulty in discarding possessions characterizes hoarding disorder; if hoarding is driven by OCD-like obsessions, an OCD diagnosis is given instead.</p>
          </list-item>
          <list-item>
            <p><bold>Eating Disorders</bold>: Unlike OCD, the focus of obsessions and compulsions in disorders like anorexia nervosa is on weight and food. Ritualized eating behaviors are associated with eating disorders.</p>
          </list-item>
          <list-item>
            <p><bold>Tic Disorders:</bold> Tics and stereotyped movements are generally less complex than compulsions and are not aimed at neutralizing obsessions. A dual diagnosis may be warranted for overlapping symptoms.</p>
          </list-item>
          <list-item>
            <p><bold>Psychotic Disorders:</bold> Although some OCD patients may have poor insight or delusional beliefs, they do not exhibit other psychotic symptoms like hallucinations.</p>
          </list-item>
          <list-item>
            <p><bold>Obsessive-compulsive personality disorder</bold>: OCD is characterized by intrusive, distressing obsessions and compulsions aimed at alleviating this distress, with individuals often recognizing their symptoms as excessive. In contrast, obsessive-compulsive personality disorder (OCPD) involves a chronic pattern of perfectionism and rigid control, without the presence of obsessions or compulsions, and is often perceived by the individual as rational and desirable.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26069.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>OCD is a chronic condition characterized by fluctuating periods of symptom exacerbation and remission. Due to this disorder, daily functioning is significantly impaired. Furthermore, OCD is associated with an elevated risk of mortality.<xref ref-type="bibr" rid="article-26069.r13">[13]</xref><xref ref-type="bibr" rid="article-26069.r63">[63]</xref>&#x000a0;Despite the utilization of CBT and SSRIs, a substantial proportion of patients remain unresponsive. Specifically, between 25% and 40% of patients do not experience symptom alleviation when treated with either CBT or SSRIs.<xref ref-type="bibr" rid="article-26069.r39">[39]</xref><xref ref-type="bibr" rid="article-26069.r13">[13]</xref>&#x000a0;Furthermore, only a minority achieve full remission, and approximately half of successfully treated patients continue to manifest residual symptoms.</p>
        <p>OCD associated with hoarding symptoms generally results&#x000a0;in a more unfavorable prognosis. Clinical data from DSM-IV field trials involving 431 patients revealed that the fear of harm was the most commonly reported obsessive symptom. A significant association between OCD and suicidal tendencies has been confirmed, with contributory factors including coexisting anxiety and depression, as well as a history of suicide attempts.<xref ref-type="bibr" rid="article-26069.r64">[64]</xref> Additionally, the association between OCD and suicidal tendencies remains significant even when controlling for depressive symptoms or mood instability.<xref ref-type="bibr" rid="article-26069.r65">[65]</xref></p>
      </sec>
      <sec id="article-26069.s11" sec-type="Complications">
        <title>Complications</title>
        <p>OCD is included in the top 10 disabling disorders by the WHO.&#x000a0;Patients with OCD tend to avoid situations that make them uncomfortable, which may lead to decreased social interactions and a poor quality of life. Most&#x000a0;who struggle with OCD&#x000a0;go undetected for years. If OCD goes untreated, the pattern is harder to break as structural changes to the brain take place.<xref ref-type="bibr" rid="article-26069.r66">[66]</xref><xref ref-type="bibr" rid="article-26069.r67">[67]</xref>&#x000a0;Duration of untreated OCD is associated with worse clinical outcomes.<xref ref-type="bibr" rid="article-26069.r68">[68]</xref> Early intervention is vital.</p>
      </sec>
      <sec id="article-26069.s12" sec-type="Consultations">
        <title>Consultations</title>
        <p>Utilizing cognitive behavioral therapy (CBT) with a focus on exposure and response prevention is the cornerstone of nonpharmacological treatment for OCD. Therefore, seeking consultation with a highly skilled and experienced therapist in administering this specialized form of therapy is crucial. Medical consultations may vary depending on the severity and specific nature of the compulsions exhibited. For instance, if a patient engages in excessive hand-washing, dermatological issues like dermatitis may arise, necessitating consultation with a dermatologist. Comprehensive treatment should address the patient holistically, encompassing psychological symptoms and any resulting medical conditions. Coordination of care with other healthcare clinicians (eg, pediatrics or family medicine) is also vital, especially for monitoring potential side effects of medications, including weight gain and tics.</p>
      </sec>
      <sec id="article-26069.s13" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>In OCD, the patient's insight is not lacking. Only 2% to 4% lack insight into their OCD.<xref ref-type="bibr" rid="article-26069.r69">[69]</xref>&#x000a0;However, most people do not seek treatment until the disorder has become severely advanced. As most symptoms present during adolescence, clinicians should inform and educate appropriate individuals, including parents, fellow medical personnel, and those in the school systems, about this disorder.</p>
      </sec>
      <sec id="article-26069.s14" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Managing OCD requires an integrated, interprofessional healthcare team to offer patient-focused care, optimize treatment outcomes, ensure patient safety, and maximize team efficiency. The team comprises primary care physicians, psychiatrists, clinical psychologists, occupational therapists, pharmacists, and social workers, each with a distinct but collaborative role. Effective communication among team members is critical for optimal patient care.</p>
        <p>Primary care physicians usually serve as the initial point of contact and are responsible for quickly identifying OCD symptoms and referring patients to specialized care. Psychiatrists oversee diagnosis and pharmacotherapy, while clinical psychologists conduct specialized psychometric tests to either confirm or rule out the OCD diagnosis, in addition to providing cognitive behavioral therapy. Clear, open communication among team members enables rapid intervention. Occupational therapists assess the patient's daily functioning, and social workers facilitate access to community resources. Pharmacists play a crucial role in managing medication interactions and ensuring medication adherence, particularly in instances of polypharmacy.</p>
        <p>Ethical considerations like obtaining informed consent are paramount, as is aligning care with autonomy, beneficence, and nonmaleficence principles. Shared decision-making is emphasized, placing patient preferences at the center of all treatment decisions. Ongoing education and professional development keep the team updated on best practices in OCD treatment. This&#x000a0;interprofessional&#x000a0;approach to OCD management prioritizes comprehensive, safe, and high-quality patient care.</p>
      </sec>
      <sec id="article-26069.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26069&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26069">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/mental-health/obsessive-compulsive-disorder/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=26069">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/26069/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=26069">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-26069.s16">
        <title>References</title>
        <ref id="article-26069.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zai</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Barta</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cath</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Eapen</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Geller</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Gr&#x000fc;nblatt</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>New insights and perspectives on the genetics of obsessive-compulsive disorder.</article-title>
            <source>Psychiatr Genet</source>
            <year>2019</year>
            <month>Oct</month>
            <volume>29</volume>
            <issue>5</issue>
            <fpage>142</fpage>
            <page-range>142-151</page-range>
            <pub-id pub-id-type="pmid">31464995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strom</surname>
                <given-names>NI</given-names>
              </name>
              <name>
                <surname>Soda</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Mathews</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>LK</given-names>
              </name>
            </person-group>
            <article-title>A dimensional perspective on the genetics of obsessive-compulsive disorder.</article-title>
            <source>Transl Psychiatry</source>
            <year>2021</year>
            <month>Jul</month>
            <day>21</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>401</fpage>
            <pub-id pub-id-type="pmid">34290223</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stein</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Costa</surname>
                <given-names>DLC</given-names>
              </name>
              <name>
                <surname>Lochner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Miguel</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>YCJ</given-names>
              </name>
              <name>
                <surname>Shavitt</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>van den Heuvel</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>HB</given-names>
              </name>
            </person-group>
            <article-title>Obsessive-compulsive disorder.</article-title>
            <source>Nat Rev Dis Primers</source>
            <year>2019</year>
            <month>Aug</month>
            <day>01</day>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>52</fpage>
            <pub-id pub-id-type="pmid">31371720</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blanco-Vieira</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Radua</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Marcelino</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Bloch</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mataix-Cols</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>do Ros&#x000e1;rio</surname>
                <given-names>MC</given-names>
              </name>
            </person-group>
            <article-title>The genetic epidemiology of obsessive-compulsive disorder: a systematic review and meta-analysis.</article-title>
            <source>Transl Psychiatry</source>
            <year>2023</year>
            <month>Jun</month>
            <day>28</day>
            <volume>13</volume>
            <issue>1</issue>
            <fpage>230</fpage>
            <pub-id pub-id-type="pmid">37380645</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mataix-Cols</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rosario-Campos</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Leckman</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>A multidimensional model of obsessive-compulsive disorder.</article-title>
            <source>Am J Psychiatry</source>
            <year>2005</year>
            <month>Feb</month>
            <volume>162</volume>
            <issue>2</issue>
            <fpage>228</fpage>
            <page-range>228-38</page-range>
            <pub-id pub-id-type="pmid">15677583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bloch</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Landeros-Weisenberger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rosario</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Pittenger</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Leckman</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Meta-analysis of the symptom structure of obsessive-compulsive disorder.</article-title>
            <source>Am J Psychiatry</source>
            <year>2008</year>
            <month>Dec</month>
            <volume>165</volume>
            <issue>12</issue>
            <fpage>1532</fpage>
            <page-range>1532-42</page-range>
            <pub-id pub-id-type="pmid">18923068</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taylor</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>McKay</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Miguel</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>De Mathis</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Andrade</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ahuja</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sookman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kwon</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Huh</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Riemann</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Cottraux</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>O'Connor</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hale</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Abramowitz</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Fontenelle</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Storch</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Musical obsessions: a comprehensive review of neglected clinical phenomena.</article-title>
            <source>J Anxiety Disord</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>28</volume>
            <issue>6</issue>
            <fpage>580</fpage>
            <page-range>580-9</page-range>
            <pub-id pub-id-type="pmid">24997394</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Greenberg</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Huppert</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Scrupulosity: a unique subtype of obsessive-compulsive disorder.</article-title>
            <source>Curr Psychiatry Rep</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>12</volume>
            <issue>4</issue>
            <fpage>282</fpage>
            <page-range>282-9</page-range>
            <pub-id pub-id-type="pmid">20544313</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fornaro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gabrielli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Albano</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Fornaro</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rizzato</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mattei</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Solano</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vinciguerra</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Fornaro</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Obsessive-compulsive disorder and related disorders: a comprehensive survey.</article-title>
            <source>Ann Gen Psychiatry</source>
            <year>2009</year>
            <month>May</month>
            <day>18</day>
            <volume>8</volume>
            <fpage>13</fpage>
            <pub-id pub-id-type="pmid">19450269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hollander</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Braun</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Simeon</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Should OCD leave the anxiety disorders in DSM-V? The case for obsessive compulsive-related disorders.</article-title>
            <source>Depress Anxiety</source>
            <year>2008</year>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>317</fpage>
            <page-range>317-29</page-range>
            <pub-id pub-id-type="pmid">18412058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Veale</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Obsessive-compulsive disorder.</article-title>
            <source>BMJ</source>
            <year>2014</year>
            <month>Apr</month>
            <day>07</day>
            <volume>348</volume>
            <fpage>g2183</fpage>
            <pub-id pub-id-type="pmid">24709802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fernandez</surname>
                <given-names>TV</given-names>
              </name>
              <name>
                <surname>Leckman</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Pittenger</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Genetic susceptibility in obsessive-compulsive disorder.</article-title>
            <source>Handb Clin Neurol</source>
            <year>2018</year>
            <volume>148</volume>
            <fpage>767</fpage>
            <page-range>767-781</page-range>
            <pub-id pub-id-type="pmid">29478613</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goodman</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Storch</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Sheth</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Harmonizing the Neurobiology and Treatment of Obsessive-Compulsive Disorder.</article-title>
            <source>Am J Psychiatry</source>
            <year>2021</year>
            <month>Jan</month>
            <day>01</day>
            <volume>178</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-29</page-range>
            <pub-id pub-id-type="pmid">33384007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahjani</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Klei</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hultman</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Larsson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Devlin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Buxbaum</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Sandin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Grice</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Maternal Effects as Causes of Risk for Obsessive-Compulsive Disorder.</article-title>
            <source>Biol Psychiatry</source>
            <year>2020</year>
            <month>Jun</month>
            <day>15</day>
            <volume>87</volume>
            <issue>12</issue>
            <fpage>1045</fpage>
            <page-range>1045-1051</page-range>
            <pub-id pub-id-type="pmid">32199606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Escobar</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Wendland</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Ch&#x000e1;vez</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Moya</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>The Neuronal Glutamate Transporter EAAT3 in Obsessive-Compulsive Disorder.</article-title>
            <source>Front Pharmacol</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>1362</fpage>
            <pub-id pub-id-type="pmid">31803055</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yuste</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>From the neuron doctrine to neural networks.</article-title>
            <source>Nat Rev Neurosci</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>16</volume>
            <issue>8</issue>
            <fpage>487</fpage>
            <page-range>487-97</page-range>
            <pub-id pub-id-type="pmid">26152865</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maraone</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tarsitani</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pinucci</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Pasquini</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Antiglutamatergic agents for obsessive-compulsive disorder: Where are we now and what are possible future prospects?</article-title>
            <source>World J Psychiatry</source>
            <year>2021</year>
            <month>Sep</month>
            <day>19</day>
            <volume>11</volume>
            <issue>9</issue>
            <fpage>568</fpage>
            <page-range>568-580</page-range>
            <pub-id pub-id-type="pmid">34631461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shitova</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Zharikova</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Kovaleva</surname>
                <given-names>ON</given-names>
              </name>
              <name>
                <surname>Luchina</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Aktemirov</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Olsufieva</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Sinelnikov</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Pontes-Silva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zharikov</surname>
                <given-names>YO</given-names>
              </name>
            </person-group>
            <article-title>Tourette syndrome and obsessive-compulsive disorder: A comprehensive review of structural alterations and neurological mechanisms.</article-title>
            <source>Behav Brain Res</source>
            <year>2023</year>
            <month>Sep</month>
            <day>13</day>
            <volume>453</volume>
            <fpage>114606</fpage>
            <pub-id pub-id-type="pmid">37524204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bird</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Shotbolt</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Epilepsy and concomitant obsessive-compulsive disorder.</article-title>
            <source>Epilepsy Behav Case Rep</source>
            <year>2018</year>
            <volume>10</volume>
            <fpage>106</fpage>
            <page-range>106-110</page-range>
            <pub-id pub-id-type="pmid">30271707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parmar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Verma</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>A Case of Obsessive-Compulsive Disorder Comorbid with Miyoshi Myopathy.</article-title>
            <source>Indian J Psychol Med</source>
            <year>2018</year>
            <season>Jan-Feb</season>
            <volume>40</volume>
            <issue>1</issue>
            <fpage>86</fpage>
            <page-range>86-88</page-range>
            <pub-id pub-id-type="pmid">29403136</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Simpson</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Slifstein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bender</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Hackett</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Maher</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Abi-Dargham</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Serotonin 2A receptors in obsessive-compulsive disorder: a positron emission tomography study with [11C]MDL 100907.</article-title>
            <source>Biol Psychiatry</source>
            <year>2011</year>
            <month>Nov</month>
            <day>01</day>
            <volume>70</volume>
            <issue>9</issue>
            <fpage>897</fpage>
            <page-range>897-904</page-range>
            <pub-id pub-id-type="pmid">21855857</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pallanti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bernardi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Antonini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hollander</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Ondansetron augmentation in patients with obsessive-compulsive disorder who are inadequate responders to serotonin reuptake inhibitors: improvement with treatment and worsening following discontinuation.</article-title>
            <source>Eur Neuropsychopharmacol</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>375</fpage>
            <page-range>375-80</page-range>
            <pub-id pub-id-type="pmid">24406025</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sakurai</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dording</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Yeung</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Trinh</surname>
                <given-names>NH</given-names>
              </name>
              <name>
                <surname>Bernard</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Boyden</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Iqbal</surname>
                <given-names>SZ</given-names>
              </name>
              <name>
                <surname>Wilkinson</surname>
                <given-names>ST</given-names>
              </name>
              <name>
                <surname>Mathew</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Mischoulon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fava</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cusin</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Longer-term open-label study of adjunctive riluzole in treatment-resistant depression.</article-title>
            <source>J Affect Disord</source>
            <year>2019</year>
            <month>Nov</month>
            <day>01</day>
            <volume>258</volume>
            <fpage>102</fpage>
            <page-range>102-108</page-range>
            <pub-id pub-id-type="pmid">31400624</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grassi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Cecchelli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Vignozzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pacini</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Investigational and Experimental Drugs to Treat Obsessive-Compulsive Disorder.</article-title>
            <source>J Exp Pharmacol</source>
            <year>2020</year>
            <volume>12</volume>
            <fpage>695</fpage>
            <page-range>695-706</page-range>
            <pub-id pub-id-type="pmid">33447096</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jalal</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chamberlain</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Sahakian</surname>
                <given-names>BJ</given-names>
              </name>
            </person-group>
            <article-title>Obsessive-compulsive disorder: Etiology, neuropathology, and cognitive dysfunction.</article-title>
            <source>Brain Behav</source>
            <year>2023</year>
            <month>Jun</month>
            <volume>13</volume>
            <issue>6</issue>
            <fpage>e3000</fpage>
            <pub-id pub-id-type="pmid">37137502</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grant</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Hook</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Valle</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Chesivoir</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chamberlain</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Tolcapone in obsessive-compulsive disorder: a randomized double-blind placebo-controlled crossover trial.</article-title>
            <source>Int Clin Psychopharmacol</source>
            <year>2021</year>
            <month>Sep</month>
            <day>01</day>
            <volume>36</volume>
            <issue>5</issue>
            <fpage>225</fpage>
            <page-range>225-229</page-range>
            <pub-id pub-id-type="pmid">34310432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murphy</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>McGuire</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Kennel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Mutch</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Parker-Athill</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Hanks</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Lewin</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Storch</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Toufexis</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Dadlani</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Rodriguez</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Characterization of the pediatric acute-onset neuropsychiatric syndrome phenotype.</article-title>
            <source>J Child Adolesc Psychopharmacol</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>25</volume>
            <issue>1</issue>
            <fpage>14</fpage>
            <page-range>14-25</page-range>
            <pub-id pub-id-type="pmid">25314221</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Fahey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Frick</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Leckman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vaccarino</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Duman</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Swedo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pittenger</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Antibodies From Children With PANDAS Bind Specifically to Striatal Cholinergic Interneurons and Alter Their Activity.</article-title>
            <source>Am J Psychiatry</source>
            <year>2021</year>
            <month>Jan</month>
            <day>01</day>
            <volume>178</volume>
            <issue>1</issue>
            <fpage>48</fpage>
            <page-range>48-64</page-range>
            <pub-id pub-id-type="pmid">32539528</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abramowitz</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>The psychological treatment of obsessive-compulsive disorder.</article-title>
            <source>Can J Psychiatry</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>51</volume>
            <issue>7</issue>
            <fpage>407</fpage>
            <page-range>407-16</page-range>
            <pub-id pub-id-type="pmid">16838822</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baxter</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Vos</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Scott</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Whiteford</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>The global burden of anxiety disorders in 2010.</article-title>
            <source>Psychol Med</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>44</volume>
            <issue>11</issue>
            <fpage>2363</fpage>
            <page-range>2363-74</page-range>
            <pub-id pub-id-type="pmid">24451993</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fairbrother</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Collardeau</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Albert</surname>
                <given-names>AYK</given-names>
              </name>
              <name>
                <surname>Challacombe</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Thordarson</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Woody</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Janssen</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>High Prevalence and Incidence of Obsessive-Compulsive Disorder Among Women Across Pregnancy and the Postpartum.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2021</year>
            <month>Mar</month>
            <day>23</day>
            <volume>82</volume>
            <issue>2</issue>
            <pub-id pub-id-type="pmid">34033273</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fawcett</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Power</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fawcett</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Women Are at Greater Risk of OCD Than Men: A Meta-Analytic Review of OCD Prevalence Worldwide.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2020</year>
            <month>Jun</month>
            <day>23</day>
            <volume>81</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">32603559</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Senter</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Dixon</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Myers</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>HB</given-names>
              </name>
            </person-group>
            <article-title>Defining and Addressing Gaps in Care for Obsessive-Compulsive Disorder in the United States.</article-title>
            <source>Psychiatr Serv</source>
            <year>2021</year>
            <month>Jul</month>
            <day>01</day>
            <volume>72</volume>
            <issue>7</issue>
            <fpage>784</fpage>
            <page-range>784-793</page-range>
            <pub-id pub-id-type="pmid">33957763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bruin</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Shock</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Zhutovsky</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Abe</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Alonso</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ameis</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Anticevic</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Arnold</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Assogna</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Benedetti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Beucke</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Boedhoe</surname>
                <given-names>PSW</given-names>
              </name>
              <name>
                <surname>Bollettini</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bose</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brem</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Brennan</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Buitelaar</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Calvo</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>KIK</given-names>
              </name>
              <name>
                <surname>Dallaspezia</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Denys</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ely</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Feusner</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Fitzgerald</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Fouche</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Fridgeirsson</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Gruner</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>G&#x000fc;rsel</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Hauser</surname>
                <given-names>TU</given-names>
              </name>
              <name>
                <surname>Hirano</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Hoexter</surname>
                <given-names>MQ</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Huyser</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ivanov</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>James</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jaspers-Fayer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kathmann</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kaufmann</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Koch</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kuno</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kvale</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kwon</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Lochner</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>L&#x000e1;zaro</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Marques</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Marsh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez-Zalaca&#x000ed;n</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mataix-Cols</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Mench&#x000f3;n</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Minuzzi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Moreira</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Morer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Morgado</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nakagawa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nakamae</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakao</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Narayanaswamy</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Nurmi</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>O'Neill</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pariente</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Perriello</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Piacentini</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Piras</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Piras</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Reddy</surname>
                <given-names>YCJ</given-names>
              </name>
              <name>
                <surname>Rus-Oswald</surname>
                <given-names>OG</given-names>
              </name>
              <name>
                <surname>Sakai</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Schmaal</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Soreni</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Soriano-Mas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Spalletta</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stern</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Stewart</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Szeszko</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Tolin</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Venkatasubramanian</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Yun</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>van Rooij</surname>
                <given-names>D</given-names>
              </name>
              <collab>ENIGMA-OCD Working Group</collab>
              <name>
                <surname>Thompson</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>van den Heuvel</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>van Wingen</surname>
                <given-names>GA</given-names>
              </name>
            </person-group>
            <article-title>Structural neuroimaging biomarkers for obsessive-compulsive disorder in the ENIGMA-OCD consortium: medication matters.</article-title>
            <source>Transl Psychiatry</source>
            <year>2020</year>
            <month>Oct</month>
            <day>08</day>
            <volume>10</volume>
            <issue>1</issue>
            <fpage>342</fpage>
            <pub-id pub-id-type="pmid">33033241</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Oliveira</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Grinberg</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Hoexter</surname>
                <given-names>MQ</given-names>
              </name>
              <name>
                <surname>Brentani</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Suemoto</surname>
                <given-names>CK</given-names>
              </name>
              <name>
                <surname>Nery</surname>
                <given-names>FG</given-names>
              </name>
              <name>
                <surname>Lima</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Alho</surname>
                <given-names>ATDL</given-names>
              </name>
              <name>
                <surname>Farfel</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Ferretti-Rebustini</surname>
                <given-names>REL</given-names>
              </name>
              <name>
                <surname>Leite</surname>
                <given-names>REP</given-names>
              </name>
              <name>
                <surname>Moretto</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>da Silva</surname>
                <given-names>AV</given-names>
              </name>
              <name>
                <surname>Lafer</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Miguel</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Nitrini</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jacob-Filho</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Heinsen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pasqualucci</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Layer-specific reduced neuronal density in the orbitofrontal cortex of older adults with obsessive-compulsive disorder.</article-title>
            <source>Brain Struct Funct</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>224</volume>
            <issue>1</issue>
            <fpage>191</fpage>
            <page-range>191-203</page-range>
            <pub-id pub-id-type="pmid">30298291</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Krebs</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Heyman</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Obsessive-compulsive disorder in children and adolescents.</article-title>
            <source>Arch Dis Child</source>
            <year>2015</year>
            <month>May</month>
            <volume>100</volume>
            <issue>5</issue>
            <fpage>495</fpage>
            <page-range>495-9</page-range>
            <pub-id pub-id-type="pmid">25398447</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heyman</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mataix-Cols</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Fineberg</surname>
                <given-names>NA</given-names>
              </name>
            </person-group>
            <article-title>Obsessive-compulsive disorder.</article-title>
            <source>BMJ</source>
            <year>2006</year>
            <month>Aug</month>
            <day>26</day>
            <volume>333</volume>
            <issue>7565</issue>
            <fpage>424</fpage>
            <page-range>424-9</page-range>
            <pub-id pub-id-type="pmid">16931840</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schruers</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Baldi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>van den Heuvel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Goossens</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Luyten</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Leentjens</surname>
                <given-names>AFG</given-names>
              </name>
              <name>
                <surname>Ackermans</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Temel</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Viechtbauer</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>The effects of deep-brain non-stimulation in severe obsessive-compulsive disorder: an individual patient data meta-analysis.</article-title>
            <source>Transl Psychiatry</source>
            <year>2019</year>
            <month>Aug</month>
            <day>05</day>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>183</fpage>
            <pub-id pub-id-type="pmid">31383848</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x000d6;st</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Havnen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kvale</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Cognitive behavioral treatments of obsessive-compulsive disorder. A systematic review and meta-analysis of studies published 1993-2014.</article-title>
            <source>Clin Psychol Rev</source>
            <year>2015</year>
            <month>Aug</month>
            <volume>40</volume>
            <fpage>156</fpage>
            <page-range>156-69</page-range>
            <pub-id pub-id-type="pmid">26117062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x000d6;st</surname>
                <given-names>LG</given-names>
              </name>
              <name>
                <surname>Riise</surname>
                <given-names>EN</given-names>
              </name>
              <name>
                <surname>Wergeland</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kvale</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Cognitive behavioral and pharmacological treatments of OCD in children: A systematic review and meta-analysis.</article-title>
            <source>J Anxiety Disord</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>43</volume>
            <fpage>58</fpage>
            <page-range>58-69</page-range>
            <pub-id pub-id-type="pmid">27632568</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hirschtritt</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Bloch</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Mathews</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Obsessive-Compulsive Disorder: Advances in Diagnosis and Treatment.</article-title>
            <source>JAMA</source>
            <year>2017</year>
            <month>Apr</month>
            <day>04</day>
            <volume>317</volume>
            <issue>13</issue>
            <fpage>1358</fpage>
            <page-range>1358-1367</page-range>
            <pub-id pub-id-type="pmid">28384832</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kvale</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bj&#x000f6;rgvinsson</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>B&#x000f8;rtveit</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hagen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Haseth</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kristensen</surname>
                <given-names>UB</given-names>
              </name>
              <name>
                <surname>Launes</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ressler</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Solem</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Strand</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>van den Heuvel</surname>
                <given-names>OA</given-names>
              </name>
              <name>
                <surname>&#x000d6;st</surname>
                <given-names>LG</given-names>
              </name>
            </person-group>
            <article-title>Successfully treating 90 patients with obsessive compulsive disorder in eight days: the Bergen 4-day treatment.</article-title>
            <source>BMC Psychiatry</source>
            <year>2018</year>
            <month>Oct</month>
            <day>04</day>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>323</fpage>
            <pub-id pub-id-type="pmid">30286745</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soomro</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Altman</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Rajagopal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Oakley-Browne</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD).</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2008</year>
            <month>Jan</month>
            <day>23</day>
            <volume>2008</volume>
            <issue>1</issue>
            <fpage>CD001765</fpage>
            <pub-id pub-id-type="pmid">18253995</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bloch</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>McGuire</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Landeros-Weisenberger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leckman</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Pittenger</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Meta-analysis of the dose-response relationship of SSRI in obsessive-compulsive disorder.</article-title>
            <source>Mol Psychiatry</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>15</volume>
            <issue>8</issue>
            <fpage>850</fpage>
            <page-range>850-5</page-range>
            <pub-id pub-id-type="pmid">19468281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stein</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>EW</given-names>
              </name>
              <name>
                <surname>Tonnoir</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Fineberg</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study.</article-title>
            <source>Curr Med Res Opin</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>701</fpage>
            <page-range>701-11</page-range>
            <pub-id pub-id-type="pmid">17407626</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Issari</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Jakubovski</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bartley</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Pittenger</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bloch</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2016</year>
            <month>May</month>
            <volume>77</volume>
            <issue>5</issue>
            <fpage>e605</fpage>
            <page-range>e605-11</page-range>
            <pub-id pub-id-type="pmid">27249090</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Varigonda</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Jakubovski</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Bloch</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Systematic Review and Meta-Analysis: Early Treatment Responses of Selective Serotonin Reuptake Inhibitors and Clomipramine in Pediatric Obsessive-Compulsive Disorder.</article-title>
            <source>J Am Acad Child Adolesc Psychiatry</source>
            <year>2016</year>
            <month>Oct</month>
            <volume>55</volume>
            <issue>10</issue>
            <fpage>851</fpage>
            <page-range>851-859.e2</page-range>
            <pub-id pub-id-type="pmid">27663940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>da Concei&#x000e7;&#x000e3;o Costa</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Shavitt</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Castro Cesar</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Joaquim</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Borcato</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Val&#x000e9;rio</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Miguel</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Diniz</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Can early improvement be an indicator of treatment response in obsessive-compulsive disorder? Implications for early-treatment decision-making.</article-title>
            <source>J Psychiatr Res</source>
            <year>2013</year>
            <month>Nov</month>
            <volume>47</volume>
            <issue>11</issue>
            <fpage>1700</fpage>
            <page-range>1700-7</page-range>
            <pub-id pub-id-type="pmid">23948637</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Batelaan</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Bosman</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Muntingh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scholten</surname>
                <given-names>WD</given-names>
              </name>
              <name>
                <surname>Huijbregts</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>van Balkom</surname>
                <given-names>AJLM</given-names>
              </name>
            </person-group>
            <article-title>Risk of relapse after antidepressant discontinuation in anxiety disorders, obsessive-compulsive disorder, and post-traumatic stress disorder: systematic review and meta-analysis of relapse prevention trials.</article-title>
            <source>BMJ</source>
            <year>2017</year>
            <month>Sep</month>
            <day>13</day>
            <volume>358</volume>
            <fpage>j3927</fpage>
            <pub-id pub-id-type="pmid">28903922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Erzegovesi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cavallini</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Cavedini</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Diaferia</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Locatelli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bellodi</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Clinical predictors of drug response in obsessive-compulsive disorder.</article-title>
            <source>J Clin Psychopharmacol</source>
            <year>2001</year>
            <month>Oct</month>
            <volume>21</volume>
            <issue>5</issue>
            <fpage>488</fpage>
            <page-range>488-92</page-range>
            <pub-id pub-id-type="pmid">11593074</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Albert</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Carmassi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Cosci</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>De Cori</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Di Nicola</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ferrari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Poloni</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tarricone</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Fiorillo</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Role and clinical implications of atypical antipsychotics in anxiety disorders, obsessive-compulsive disorder, trauma-related, and somatic symptom disorders: a systematized review.</article-title>
            <source>Int Clin Psychopharmacol</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>31</volume>
            <issue>5</issue>
            <fpage>249</fpage>
            <page-range>249-58</page-range>
            <pub-id pub-id-type="pmid">26974213</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dold</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Aigner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lanzenberger</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kasper</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Antipsychotic Augmentation of Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: An Update Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials.</article-title>
            <source>Int J Neuropsychopharmacol</source>
            <year>2015</year>
            <month>May</month>
            <day>04</day>
            <volume>18</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">25939614</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Diniz</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Shavitt</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Fossaluza</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Koran</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pereira</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Miguel</surname>
                <given-names>EC</given-names>
              </name>
            </person-group>
            <article-title>A double-blind, randomized, controlled trial of fluoxetine plus quetiapine or clomipramine versus fluoxetine plus placebo for obsessive-compulsive disorder.</article-title>
            <source>J Clin Psychopharmacol</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>31</volume>
            <issue>6</issue>
            <fpage>763</fpage>
            <page-range>763-8</page-range>
            <pub-id pub-id-type="pmid">22020357</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Costa</surname>
                <given-names>DLC</given-names>
              </name>
              <name>
                <surname>Diniz</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Requena</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Joaquim</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Pittenger</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bloch</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Miguel</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Shavitt</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Randomized, Double-Blind, Placebo-Controlled Trial of N-Acetylcysteine Augmentation for Treatment-Resistant Obsessive-Compulsive Disorder.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>78</volume>
            <issue>7</issue>
            <fpage>e766</fpage>
            <page-range>e766-e773</page-range>
            <pub-id pub-id-type="pmid">28617566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dunlop</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Woodside</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Olmsted</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Colton</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Giacobbe</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Downar</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Reductions in Cortico-Striatal Hyperconnectivity Accompany Successful Treatment of Obsessive-Compulsive Disorder with Dorsomedial Prefrontal rTMS.</article-title>
            <source>Neuropsychopharmacology</source>
            <year>2016</year>
            <month>Apr</month>
            <volume>41</volume>
            <issue>5</issue>
            <fpage>1395</fpage>
            <page-range>1395-403</page-range>
            <pub-id pub-id-type="pmid">26440813</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Carmi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Tendler</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bystritsky</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hollander</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Blumberger</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Daskalakis</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lapidus</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Casuto</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Feifel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Barnea-Ygael</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zangen</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zohar</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial.</article-title>
            <source>Am J Psychiatry</source>
            <year>2019</year>
            <month>Nov</month>
            <day>01</day>
            <volume>176</volume>
            <issue>11</issue>
            <fpage>931</fpage>
            <page-range>931-938</page-range>
            <pub-id pub-id-type="pmid">31109199</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McCathern</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Mathai</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>RY</given-names>
              </name>
              <name>
                <surname>Goodman</surname>
                <given-names>WK</given-names>
              </name>
              <name>
                <surname>Storch</surname>
                <given-names>EA</given-names>
              </name>
            </person-group>
            <article-title>Deep transcranial magnetic stimulation for obsessive compulsive disorder.</article-title>
            <source>Expert Rev Neurother</source>
            <year>2020</year>
            <month>Oct</month>
            <volume>20</volume>
            <issue>10</issue>
            <fpage>1029</fpage>
            <page-range>1029-1036</page-range>
            <pub-id pub-id-type="pmid">32684005</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brown</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Mikell</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Youngerman</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>McKhann</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Sheth</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Dorsal anterior cingulotomy and anterior capsulotomy for severe, refractory obsessive-compulsive disorder: a systematic review of observational studies.</article-title>
            <source>J Neurosurg</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>124</volume>
            <issue>1</issue>
            <fpage>77</fpage>
            <page-range>77-89</page-range>
            <pub-id pub-id-type="pmid">26252455</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Miguel</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Lopes</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>McLaughlin</surname>
                <given-names>NCR</given-names>
              </name>
              <name>
                <surname>Nor&#x000e9;n</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gentil</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Hamani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shavitt</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Batistuzzo</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Vattimo</surname>
                <given-names>EFQ</given-names>
              </name>
              <name>
                <surname>Canteras</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>De Salles</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gorgulho</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Salvajoli</surname>
                <given-names>JV</given-names>
              </name>
              <name>
                <surname>Fonoff</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Paddick</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hoexter</surname>
                <given-names>MQ</given-names>
              </name>
              <name>
                <surname>Lindquist</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Haber</surname>
                <given-names>SN</given-names>
              </name>
              <name>
                <surname>Greenberg</surname>
                <given-names>BD</given-names>
              </name>
              <name>
                <surname>Sheth</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Evolution of gamma knife capsulotomy for intractable obsessive-compulsive disorder.</article-title>
            <source>Mol Psychiatry</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>218</fpage>
            <page-range>218-240</page-range>
            <pub-id pub-id-type="pmid">29743581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Denys</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Graat</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Mocking</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>de Koning</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Vulink</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Figee</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ooms</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mantione</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>van den Munckhof</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Schuurman</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of Deep Brain Stimulation of the Ventral Anterior Limb of the Internal Capsule for Refractory Obsessive-Compulsive Disorder: A Clinical Cohort of 70 Patients.</article-title>
            <source>Am J Psychiatry</source>
            <year>2020</year>
            <month>Mar</month>
            <day>01</day>
            <volume>177</volume>
            <issue>3</issue>
            <fpage>265</fpage>
            <page-range>265-271</page-range>
            <pub-id pub-id-type="pmid">31906709</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r61">
          <label>61</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Baldermann</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Kibleur</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Treu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Akram</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Elias</surname>
                <given-names>GJB</given-names>
              </name>
              <name>
                <surname>Boutet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lozano</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Al-Fatly</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Strange</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Barcia</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Zrinzo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Joyce</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Chabardes</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Visser-Vandewalle</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Polosan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kuhn</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>K&#x000fc;hn</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Horn</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A unified connectomic target for deep brain stimulation in obsessive-compulsive disorder.</article-title>
            <source>Nat Commun</source>
            <year>2020</year>
            <month>Jul</month>
            <day>03</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>3364</fpage>
            <pub-id pub-id-type="pmid">32620886</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r62">
          <label>62</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tyagi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Apergis-Schoute</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Akram</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Foltynie</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Limousin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Drummond</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Fineberg</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Matthews</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jahanshahi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Robbins</surname>
                <given-names>TW</given-names>
              </name>
              <name>
                <surname>Sahakian</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Zrinzo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hariz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Joyce</surname>
                <given-names>EM</given-names>
              </name>
            </person-group>
            <article-title>A Randomized Trial Directly Comparing Ventral Capsule and Anteromedial Subthalamic Nucleus Stimulation in Obsessive-Compulsive Disorder: Clinical and Imaging Evidence for Dissociable Effects.</article-title>
            <source>Biol Psychiatry</source>
            <year>2019</year>
            <month>May</month>
            <day>01</day>
            <volume>85</volume>
            <issue>9</issue>
            <fpage>726</fpage>
            <page-range>726-734</page-range>
            <pub-id pub-id-type="pmid">30853111</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r63">
          <label>63</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Meier</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Mattheisen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mors</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Schendel</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Mortensen</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Plessen</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>Mortality Among Persons With Obsessive-Compulsive Disorder in Denmark.</article-title>
            <source>JAMA Psychiatry</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>73</volume>
            <issue>3</issue>
            <fpage>268</fpage>
            <page-range>268-274</page-range>
            <pub-id pub-id-type="pmid">26818216</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r64">
          <label>64</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Torres</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Prince</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Bebbington</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Bhugra</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Brugha</surname>
                <given-names>TS</given-names>
              </name>
              <name>
                <surname>Farrell</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Meltzer</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Singleton</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Obsessive-compulsive disorder: prevalence, comorbidity, impact, and help-seeking in the British National Psychiatric Morbidity Survey of 2000.</article-title>
            <source>Am J Psychiatry</source>
            <year>2006</year>
            <month>Nov</month>
            <volume>163</volume>
            <issue>11</issue>
            <fpage>1978</fpage>
            <page-range>1978-85</page-range>
            <pub-id pub-id-type="pmid">17074950</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r65">
          <label>65</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bowen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rahman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>LY</given-names>
              </name>
              <name>
                <surname>Khalaj</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Baetz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Peters</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Balbuena</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Suicidality in People With Obsessive-Compulsive Symptoms or Personality Traits.</article-title>
            <source>Front Psychiatry</source>
            <year>2018</year>
            <volume>9</volume>
            <fpage>747</fpage>
            <pub-id pub-id-type="pmid">30692943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r66">
          <label>66</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakao</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Okada</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kanba</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Neurobiological model of obsessive-compulsive disorder: evidence from recent neuropsychological and neuroimaging findings.</article-title>
            <source>Psychiatry Clin Neurosci</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>68</volume>
            <issue>8</issue>
            <fpage>587</fpage>
            <page-range>587-605</page-range>
            <pub-id pub-id-type="pmid">24762196</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r67">
          <label>67</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fineberg</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Apergis-Schoute</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Vaghi</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Banca</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gillan</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Voon</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Chamberlain</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Cinosi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shahper</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bullmore</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Sahakian</surname>
                <given-names>BJ</given-names>
              </name>
              <name>
                <surname>Robbins</surname>
                <given-names>TW</given-names>
              </name>
            </person-group>
            <article-title>Mapping Compulsivity in the DSM-5 Obsessive Compulsive and Related Disorders: Cognitive Domains, Neural Circuitry, and Treatment.</article-title>
            <source>Int J Neuropsychopharmacol</source>
            <year>2018</year>
            <month>Jan</month>
            <day>01</day>
            <volume>21</volume>
            <issue>1</issue>
            <fpage>42</fpage>
            <page-range>42-58</page-range>
            <pub-id pub-id-type="pmid">29036632</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r68">
          <label>68</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perris</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cipolla</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Catapano</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sampogna</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Luciano</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Giallonardo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Del Vecchio</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Fabrazzo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fiorillo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Catapano</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Duration of Untreated Illness in Patients with Obsessive-Compulsive Disorder and Its Impact on Long-Term Outcome: A Systematic Review.</article-title>
            <source>J Pers Med</source>
            <year>2023</year>
            <month>Sep</month>
            <day>29</day>
            <volume>13</volume>
            <issue>10</issue>
            <pub-id pub-id-type="pmid">37888064</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26069.r69">
          <label>69</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van Ameringen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Patterson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>DSM-5 obsessive-compulsive and related disorders: clinical implications of new criteria.</article-title>
            <source>Depress Anxiety</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>31</volume>
            <issue>6</issue>
            <fpage>487</fpage>
            <page-range>487-93</page-range>
            <pub-id pub-id-type="pmid">24616177</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
